

DAFTAR PUSTAKA

1. Widjanarko A, Sudoyo AW, Salonder H. Buku Ajar Ilmu Penyakit Dalam. VI. Setiati S, editor. Jakarta: InternaPublisihing; 2014. 2648 p.
2. Supandiman I. Hematologi Klinik. 2nd ed. Bandung: P. T. Alumni; 1997. 95–101 p.
3. Marsh JCW, Ball SE, Darbyshire P, Gordon-Smith EC, Keidan AJ, Martin A, et al. Guidelines for the diagnosis and management of acquired aplastic anaemia. *Br J Haematol.* 2003;123(5):782–801.
4. Kwon JH, Kim I, Lee YG, Koh Y, Park HC, Song EY, et al. Clinical course of non-severe aplastic anemia in adults. *Int J Hematol.* 2010;91(5):770–5.
5. Bhatnagar SK, Chandra J, Narayan S, Sharma S, Singh V, Dutta AK. Pancytopenia in Children: Etiological Profile. *J Trop Pediatr.* 2005;51(4):236–9.
6. Kee JL. Pedoman pemeriksaan laboratorium dan diagnostik. 6th ed. Kapoh RP, editor. Jakarta: EGC; 2007. 129–132 p.
7. Dearasi Deby NF N. Indeks Produksi Retikulosit Sebagai Diagnosis Dini Anemia Aplastik. *Majority.* 2015;4(7):55–60.
8. Thaha, Lestari AW, Yasa IWPS. Diagnosis, Diagnosis Differensial dan Penatalaksanaan Immunosupresif dan Terapi Sumsum Tulang pada Pasien Anemia Aplastik. *Patol Klin Fak Kedokt Univ Udayana.* 2012;5(3):22–33.
9. Bakta IM. Hematologi Klinik Ringkas. Jakarta: EGC; 2015. 98–109 p.
10. Longo DL. Harrison's Hematology and Oncology. 3rd ed. United States: McGraw Hill Companies; 2016. 128–136 p.
11. Rahim A, Suaniti N, Susanah Rita W. Analisis Fenol Dalam Urin Pekerja Salah Satu Stasiun Pengisian Bahan Bakar Umum Di Kota Denpasar. *J Kim.* 2015;9(1):105–8.
12. Supandiman I. Pedoman Diagnosis dan Terapi Hematologi Onkologi Medik. Jakarta: Q-communication; 2003. 6 p.
13. Silliman CC, Voelkel NF, Allard JD, Elzi DJ, Tuder RM, Johnson JL, et al. Plasma and lipids from stored packed red blood cells cause acute lung injury in an animal model. *J Clin Invest.* 1998;101(7):1458–67.

14. Rauff B, Idrees M, Shah SAR, Butt S, Butt AM, Ali L, et al. Hepatitis Associated Aplastic Anemia: A review. Virol J. 2011;8(1):87.
15. Bauw N, Candra A. Hubungan asupan mikronutrien dengan jenis anemia pada ibu hamil. J Kedokt Diponegoro. 2017;6(2):993–1000.
16. Riveros-Perez E, Hermesch AC, Barbour LA, Hawkins J. Aplastic anemia during pregnancy: a review of obstetric and anesthetic considerations. Int J Womens Health. 2018 Feb;10:117–25.
17. Shadduck L. Aplastic anemia. In: Lichtman M, Beutler E, editors. William Hematology. 7th ed. New York: McGraw Hill Medical; 2015. p. 513–33.
18. Fleming A. Hypoplastic anaemia in pregnancy. In: Jepson J, editor. Clinics in Hematology. 2nd ed. London; 1973. p. 477–96.
19. Munker R, Hiller E, Paquette R, Glass J. Aplastic Anemias. In: Munker R, Hiller E, editors. Modern Hematology. 2nd ed. Totowa, New Jersey: Humana Press; 2007. p. 207–16.
20. Young NS, Bacigalupo A, Marsh JCW. Aplastic Anemia: Pathophysiology and Treatment. Biol Blood Marrow Transplant. 2010;16(1):119–25.
21. Kumar V, Contran R, Robbin S. Gangguan Eritrosit. In: Buku Ajar Patologi. 7th ed. Jakarta: EGC; 2007. p. 189–1.
22. Dinca AL, Marginean OC, Melit LE, Damian R, Chincesan M. Case Presentations Aplastic Anaemia: Therapeutic and Deontological Aspects. Rom J Pediatr. 2016;65(1):56–9.
23. Lanzkowsky P. Lanzkowsky's Manual of Pediatric Hematology and Oncology. 6th ed. Massachusetts: Academic Press; 2016. 123–167 p.
24. Rai A, Vaishali V, Naikmasur VG, Kumar A, Sattur A. Aplastic anemia presenting as bleeding of gingiva: Case report and dental considerations. Saudi J Dent Res. 2016;7(1):69–72.
25. Fauzi MR. Diagnosis Dan Indikasi Transfusi Darah. E-Jurnal Med Udayana. 2013;2:13–4.
26. Cohn CS, Stubbs J, Schwartz J, Francis R, Goss C, Cushing M, et al. A comparison of adverse reaction rates for PAS C versus plasma platelet units. Transfusion. 2014;54(8):1927–34.
27. Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of

- infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. *Transfusion*. 2002;42(8):975–9.
28. Lemaistre C, Paul S, Anthony S. Severe Aplastic Anemia. *Natl Marrow Donor Progr*. 2010;
 29. Baak YM, Ahn BY, Chang HS, Kim JH, Kim KA, Lim Y. Aplastic Anemia in a Petrochemical Factory Worker. *Environ Health Perspect*. 1999;107(10):1998–2000.
 30. Eman S. Genotoxic effects of occupational exposure to benzene in gasoline station workers. *J Stage*. 2017;13(2):73–5.
 31. Martí-Carvajal AJ, Solà I, González LE, Leon de Gonzalez G, Rodriguez-Malagon N. Pharmacological interventions for the prevention of allergic and febrile non-haemolytic transfusion reactions. *Cochrane Database Syst Rev*. 2010;(6).
 32. Aaron AR, Tobian M, Karen E, King M, Paul MN. Prevention of febrile nonhemolytic and allergic transfusion reactions with pretransfusion medication: is this evidence-based medicine? *Transfusion*. 2008;48(11):2274–6.
 33. Goldman M, Webert KE, Arnold DM, Freedman J, Hannon J, Blajchman MA. Proceedings of a Consensus Conference: Towards an Understanding of TRALI. *Transfus Med Rev*. 2005 Jan;19(1):2–31.
 34. Savage WJ, Tobian AAR, Savage JH, Wood RA, Schroeder JT, Ness PM. Scratching the surface of allergic transfusion reactions. *Transfusion*. 2013 Jun;53(6):1361–71.
 35. Herwaldt BL, Linden J V., Bosserman E, Young C, Olkowska D, Wilson M. Transfusion-Associated Babesiosis in the United States: A Description of Cases. *Ann Intern Med*. 2011;155(8):509.
 36. Spivak J. Recombinant human erythropoietin and its role in transfusion medicine. *Transfusion*. 1994 Jan;34(1):1–4.
 37. Flesland O. A comparison of complication rates based on published haemovigilance data. *Intensive Care Med*. 2007;33(1):17–21.
 38. Young NS. Immune pathophysiology of acquired aplastic anaemia. *Eur J*

- Haematol [Internet]. 2009 Apr 24;57(60):55–9. Available from: <http://doi.wiley.com/10.1111/j.1600-0609.1996.tb01646.x>
39. Young NS, Maciejewski J. The Pathophysiology of Acquired Aplastic Anemia. Epstein FH, editor. *N Engl J Med.* 1997;336(19):1365–72.
40. Salonder H. Anemia Aplastik. In: Sudoyo A, Setiyohadi B, editors. *Buku Ajar Ilmu Penyakit Dalam Jilid I.* 6th ed. Jakarta: Interna Publishing; 2014. p. 637–43.
41. AlKhouri N, Ericson S. Aplastic anemia: review of etiology and treatment. *Hosp Physician.* 1999;35:46–52.
42. Böttiger LE, Böttiger B. Incidence and Cause of Aplastic Anemia, Hemolytic Anemia, Agranulocytosis and Thrombocytopenia. *Acta Med Scand.* 1981;210(1–6):475–9.
43. Burkhardt R, Kettner G, Böhm W, Schmidmeier M, Schlag R, Frisch B, et al. Changes in trabecular bone, hematopoiesis and bone marrow vessels in aplastic anemia, primary osteoporosis, and old age: A comparative histomorphometric study. *Bone.* 1987;8(3):157–64.
44. Wang J, Shen P, Wu X, Jin W. Risk factors associated with poor response to immunosuppressive therapy in acquired aplastic anemia: A meta-analysis of retrospective studies. *Exp Ther Med.* 2020;3104–12.
45. Risitano A. Immunosuppressive therapies in the management of immunemediated marrow failures in adults: Where we stand and where we are going. *Br J Haematol.* 2011;152:127–40.
46. Townsley D, Dumitriu B, Young N. Bone marrow failure and the telomeropathies. *Blood.* 2014;124:2775–83.
47. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. *Blood.* 2006 Oct 15;108(8):2509–19.
48. Young NS. Pathophysiologic Mechanisms in Acquired Aplastic Anemia. *Hematology [Internet].* 2006 Jan 1;2006(1):72–7. Available from: <https://ashpublications.org/hematology/article/2006/1/72/19811/Pathophysiologic-Mechanisms-in-Acquired-Aplastic>
49. den Elzen WPJ, Gussekloo J. Anaemia in older persons. *Neth J Med.* 2011

- Jun;69(6):260–7.
50. Jaime-Pérez JC, Colunga-Pedraza PR, Gómez-Ramírez CD, Gutiérrez-Aguirre CH, Cantú-Rodríguez OG, Tarín-Arzaga LC, et al. Danazol as first-line therapy for aplastic anemia. *Ann Hematol*. 2011;90(5):523–7.
 51. Yuantari MC. Dampak Pestisida Organoklorin Terhadap Kesehatan Manusia dan Lingkungan Serta Penanggulangannya. *Pros Semin Nas*. 2011;187–99.
 52. Fleming LE, Timmeny W. Aplastic Anemia and Pesticides. *J Occup Environ Med*. 1993;35(11):1106–16.
 53. Gallicchio VS, Casale GP, Watts T. Inhibition of human bone marrow-derived stem cell colony formation (CFU-E, BFU-E, and CFU-GM) following in vitro exposure to organophosphates. *Exp Hematol*. 1987;15(11):1099–102.
 54. Sharpe WD. Benzene, artificial leather and aplastic anemia: Newark, 1916–1928. *Bull N Y Acad Med*. 1993;69(1):47–60.
 55. Young N, Calado R, Scheinberg P. Why does the bone marrow fail in Fanconi anemia? *Blood* 108:2509, 2006. *Blood*. 2006;108(2509).
 56. Rauff B, Idrees M, Shah SAR, Butt S, Butt AM, Ali L, et al. Hepatitis Associated Aplastic Anemia: A review. *Virol J*. 2011;8(1):87.
 57. Locasciulli A, Bacigalupo A, Bruno B, Montante B, Marsh J, Tichelli A, et al. Hepatitis-associated aplastic anaemia: epidemiology and treatment results obtained in Europe. A report of The EBMT aplastic anaemia working party. *Br J Haematol*. 2010 Feb 9;149(6):890–5.
 58. Lowenthal RM, Eaton K. Toxicity of chemotherapy. *Hematol Oncol Clin North Am*. 1996;10(4):967–90.
 59. Prihartono N, Kriebel D, Woskie S, Thetkhathuek A, Sripaung N, Padungtod C, et al. Risk of aplastic anemia and pesticide and other chemical exposures. *Asia-Pacific J Public Heal*. 2011;23(3):369–77.
 60. Bass JK, Ortega L, Rosales C, Petersen NJ, Philen RM. What's being used at home: A household pesticide survey. *Rev Panam Salud Publica/Pan Am J Public Heal*. 2001;9(3):138–44.
 61. Jaga K, Dharmani C. Sources of exposure to and public health implications of organophosphate pesticides. *Rev Panam Salud Publica/Pan Am J Public*

- Heal. 2003;14(3):171–85.
62. Issaragrisil S, Kaufman DW, Anderson T, Chansung K, Leaverton PE, Shapiro S, et al. The epidemiology of aplastic anemia in Thailand. *Blood*. 2006;107(4):1299–307.
63. Friberg R, Dodson V. Cytogenetic studies of rats injected with lindane. *OXICOLOGY Appl Pharmacol*. 1966;8(2):341.
64. Traczyk Z, Rudowski W. Organochlorine insecticides as potential factors influencing blood cell functions. *Acta Physiol Pol*. 1979;30:111–8.
65. Garry V, Nelson R, Griffith J, Harkins M. Preparation for human study of pesticide applicators: sister chromatid exchanges and chromosome aberrations in cultured human lymphocytes exposed to selected fumigants. *Teratog Carcinog Mutagen*. 1990;10:21–9.
66. Fisher D, Mueller G. Gamma hexachlorocyclohexane inhibits the initiation of lymphocyte growth by phytohemagglutinin. *Biochem Pharmacol*. 1971;20:2515–8.
67. Guiguet M, Baumelou E, Mary JY. A case-control study of aplastic anaemia: Occupational exposures. *Int J Epidemiol*. 1995;24(5):993–9.
68. Vaht K, Göransson M, Carlson K, Isaksson C, Lenhoff S, Sandstedt A, et al. Incidence and outcome of acquired aplastic anemia: Real-world data from patients diagnosed in Sweden from 2000–2011. *Haematologica*. 2017;102(10):1683–90.
69. Adnyani DAP, Herawati S, Wirawati IAP. Pasien Anemia Aplastik Yang Dirawat Di Rsup Sanglah Tahun 2016. *E-Jurnal Med Udayana*. 2019;8(5):1–9.
70. Ashwini B, Seetu P, Siddiq MA. Aplastic Anemia in a Developing Country : The Present and the Need. *Natl J Lab Med*. 2016;5(3):8–10.
71. Howard SC, Naidu PE, Hu XJ, Jeng MR, Rodriguez-Galindo C, Rieman MD, et al. Natural history of moderate aplastic anemia in children. *Pediatr Blood Cancer*. 2004;43(5):545–51.
72. DeZern AE, Guinan EC. Aplastic anemia in adolescents and young adults. *Acta Haematol*. 2014;132(3–4):331–9.
73. Jalaeikhoo H, Khajeh-Mehrizi A. Immunosuppressive Therapy in Patients

with Aplastic Anemia: A Single-Center Retrospective Study. del Cañizo MC, editor. PLoS One. 2015 May 13;10(5):1–10.

